After the first part of this year’s Generics Bulletin Top 50 showed a stable top ten of generics and biosimilars firms – albeit with much happening under the surface – and the second part reflected some ups and downs for our mid-table players (see sidebar), this third section of our annual feature shows a couple of companies exiting the ranking altogether at the bottom of the table in 2023.
The Generics Bulletin Top 50, Part Three: Firms Fall Out Of Final Grouping
A Pair Of Firms Disappear From Our Annual Ranking As Other Companies Enter The Fray
In the third instalment of this year’s Generics Bulletin Top 50, we look at some of the firms that have been eliminated from the bottom of our table as others have entered the picture.
More from Generics
More from Products
• By
India’s Dr Reddy’s and China’s Bio-Thera have struck a deal covering ustekinumab and golimumab biosimilars in multiple markets in south-east Asia.
• By
Fresenius Kabi has met its end of the bargain to launch biosimilars to Prolia/Xgeva in the middle of this year, after bagging FDA approvals. The German firm is also set to hear back on its filings in Europe imminently.
• By
Alvotech and Advanz have announced a UK MHRA filing acceptance for their partnered AVT23 proposed biosimilar to Xolair (omalizumab).